213 related articles for article (PubMed ID: 11756419)
1. Structural basis for neurofibromatosis type 2. Crystal structure of the merlin FERM domain.
Shimizu T; Seto A; Maita N; Hamada K; Tsukita S; Tsukita S; Hakoshima T
J Biol Chem; 2002 Mar; 277(12):10332-6. PubMed ID: 11756419
[TBL] [Abstract][Full Text] [Related]
2. Evolution and origin of merlin, the product of the Neurofibromatosis type 2 (NF2) tumor-suppressor gene.
Golovnina K; Blinov A; Akhmametyeva EM; Omelyanchuk LV; Chang LS
BMC Evol Biol; 2005 Dec; 5():69. PubMed ID: 16324214
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of the binding of Merlin FERM domain to the E3 ubiquitin ligase substrate adaptor DCAF1.
Li Y; Wei Z; Zhang J; Yang Z; Zhang M
J Biol Chem; 2014 May; 289(21):14674-81. PubMed ID: 24706749
[TBL] [Abstract][Full Text] [Related]
4. Unfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the merlin tumor suppressor.
Yogesha SD; Sharff AJ; Giovannini M; Bricogne G; Izard T
Protein Sci; 2011 Dec; 20(12):2113-20. PubMed ID: 22012890
[TBL] [Abstract][Full Text] [Related]
5. The structure of the FERM domain of merlin, the neurofibromatosis type 2 gene product.
Kang BS; Cooper DR; Devedjiev Y; Derewenda U; Derewenda ZS
Acta Crystallogr D Biol Crystallogr; 2002 Mar; 58(Pt 3):381-91. PubMed ID: 11856822
[TBL] [Abstract][Full Text] [Related]
6. Fluorescence resonance energy transfer analysis of merlin conformational changes.
Hennigan RF; Foster LA; Chaiken MF; Mani T; Gomes MM; Herr AB; Ip W
Mol Cell Biol; 2010 Jan; 30(1):54-67. PubMed ID: 19884346
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of DDB1-and-Cullin 4-associated Factor 1 (DCAF1) recognition by merlin/NF2 and its implication in tumorigenesis by CD44-mediated inhibition of merlin suppression of DCAF1 function.
Mori T; Gotoh S; Shirakawa M; Hakoshima T
Genes Cells; 2014 Aug; 19(8):603-19. PubMed ID: 24912773
[TBL] [Abstract][Full Text] [Related]
8. Interaction between two isoforms of the NF2 tumor suppressor protein, merlin, and between merlin and ezrin, suggests modulation of ERM proteins by merlin.
Meng JJ; Lowrie DJ; Sun H; Dorsey E; Pelton PD; Bashour AM; Groden J; Ratner N; Ip W
J Neurosci Res; 2000 Nov; 62(4):491-502. PubMed ID: 11070492
[TBL] [Abstract][Full Text] [Related]
9. The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex.
Gladden AB; Hebert AM; Schneeberger EE; McClatchey AI
Dev Cell; 2010 Nov; 19(5):727-39. PubMed ID: 21074722
[TBL] [Abstract][Full Text] [Related]
10. Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function.
Surace EI; Haipek CA; Gutmann DH
Oncogene; 2004 Jan; 23(2):580-7. PubMed ID: 14724586
[TBL] [Abstract][Full Text] [Related]
11. Novel neurofibromatosis type 2 mutation presenting with status epilepticus.
DiFrancesco JC; Sestini R; Cossu F; Bolognesi M; Sala E; Mariani S; Saracchi E; Papi L; Ferrarese C
Epileptic Disord; 2014 Mar; 16(1):132-7. PubMed ID: 24667735
[TBL] [Abstract][Full Text] [Related]
12. Self-masking in an intact ERM-merlin protein: an active role for the central alpha-helical domain.
Li Q; Nance MR; Kulikauskas R; Nyberg K; Fehon R; Karplus PA; Bretscher A; Tesmer JJ
J Mol Biol; 2007 Feb; 365(5):1446-59. PubMed ID: 17134719
[TBL] [Abstract][Full Text] [Related]
13. The tumour suppressor protein NF2/merlin: the puzzle continues.
Hovens CM; Kaye AH
J Clin Neurosci; 2001 Jan; 8(1):4-7. PubMed ID: 11148074
[TBL] [Abstract][Full Text] [Related]
14. FERM domain phosphoinositide binding targets merlin to the membrane and is essential for its growth-suppressive function.
Mani T; Hennigan RF; Foster LA; Conrady DG; Herr AB; Ip W
Mol Cell Biol; 2011 May; 31(10):1983-96. PubMed ID: 21402777
[TBL] [Abstract][Full Text] [Related]
15. The crystal structure of the FERM and C-terminal domain complex of Drosophila Merlin.
Zhang F; Liu B; Gao Y; Long J; Zhou H
Biochem Biophys Res Commun; 2021 May; 553():92-98. PubMed ID: 33765559
[TBL] [Abstract][Full Text] [Related]
16. NF2: the wizardry of merlin.
Xiao GH; Chernoff J; Testa JR
Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of neurofibromatosis 2 (NF2) missense mutations.
Gutmann DH; Hirbe AC; Haipek CA
Hum Mol Genet; 2001 Jul; 10(14):1519-29. PubMed ID: 11448944
[TBL] [Abstract][Full Text] [Related]
18. [Neurofibromatosis type 2 (NF2)].
Araki N; Takeshima H; Saya H
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1427-31. PubMed ID: 9309136
[TBL] [Abstract][Full Text] [Related]
19. Two Sides of the Coin: Ezrin/Radixin/Moesin and Merlin Control Membrane Structure and Contact Inhibition.
Michie KA; Bermeister A; Robertson NO; Goodchild SC; Curmi PMG
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31018575
[TBL] [Abstract][Full Text] [Related]
20. The merlin interacting proteins reveal multiple targets for NF2 therapy.
Scoles DR
Biochim Biophys Acta; 2008 Jan; 1785(1):32-54. PubMed ID: 17980164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
